脑基因表达与DNA甲基化同晚年认知下降中离体MRI横向弛豫改变的相关性
基于两个社区队列的尸检脑组织研究,分析离体MRI横向弛豫率(R2)与基因表达和DNA甲基化的关联。发现四个共表达基因的高表达与较慢R2相关,加入基因表达信号后R2与认知下降的关联减弱;DNA甲基化扫描未检出全基因组显著信号,但R2与多个CpG位点甲基化呈反相关。
要点
- 四个共表达基因(PADI2、ZNF385A、PSD2、A2ML1)高表达与较慢R2相关。
- 加入基因表达信号后,R2与认知下降的关联系数从0.028降至0.019。
- DNA甲基化扫描未检出全基因组显著信号,但R2与多个CpG位点甲基化呈反相关。
核心结论
- 脑基因表达和DNA甲基化失调与晚年认知下降相关的脑组织属性改变有关,且独立于常见神经病理状况。
研究设计与样本
- 基因表达分析限于174例同时有成像和脑RNA测序数据的个体;DNA甲基化分析限于225例同时有成像和脑甲基化数据的个体。
- 离体MRI横向弛豫图采用快速自旋回波成像生成,目标为控制常见神经病理状况后与认知下降相关的横向弛豫率(R2)复合指标。
- 采用下一代RNA测序和DNA甲基化数据(背外侧前额叶皮层冷冻组织),全基因组关联分析分别探究基因表达和DNA甲基化与R2的关联信号。
主要发现
- 552例离体成像个体中,女性394例、男性158例,死亡时平均(SD)年龄90.4(6.0)岁。
- 鉴定出四个共表达基因(PADI2、ZNF385A、PSD2、A2ML1),其较高表达与较慢R2相关。
- 加入基因表达信号后,R2与认知下降的关联减弱,平均(SE)系数从0.028(0.008)(P < .001)降至0.019(0.009)(P = .03)。
- DNA甲基化扫描未检出全基因组显著信号,但显示R2与许多胞嘧啶-鸟嘌呤二核苷酸位点的DNA甲基化呈反相关。
临床怎么用
- 提示脑基因表达和DNA甲基化失调可能参与晚年认知下降相关的脑组织属性改变,独立于常见神经病理状况。
- 为理解晚年认知下降的神经生物学机制提供了基因表达和DNA甲基化层面的线索。
局限性
- 基因表达分析仅限174例、DNA甲基化分析仅限225例,样本量有限。
- DNA甲基化扫描未检出全基因组显著信号。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Alteration of ex vivo magnetic resonance imaging transverse relaxation is associated with late-life cognitive decline even after controlling for common neuropathologic conditions. However, the underlying neurobiology of this association is unknown. OBJECTIVE: To investigate the association between brain gene expression, DNA methylation, and alteration of magnetic resonance imaging transverse relaxation in late-life cognitive decline. DESIGN, SETTING, AND PARTICIPANTS: Data came from 2 community-based longitudinal cohort studies of aging and dementia, the Religious Orders Study, which began in 1993, and the Rush Memory and Aging Project, which began in 1997. All participants agreed to undergo annual clinical evaluations and to donate their brains after death. By October 24, 2016, a total of 1358 individuals had died and had brain autopsies that were approved by board-certified neuropathologists. Of those, 552 had undergone ex vivo imaging. The gene expression analysis was limited to 174 individuals with both imaging and brain RNA sequencing data. The DNA methylation analysis was limited to 225 individuals with both imaging and brain methylation data. MAIN OUTCOMES AND MEASURES: Maps of ex vivo magnetic resonance imaging transverse relaxation were generated using fast spin echo imaging. The target was a composite measure of the transverse relaxation rate (R2) that was associated with cognitive decline after controlling for common neuropathologic conditions. Next-generation RNA sequencing and DNA methylation data were generated using frozen tissue from the dorsolateral prefrontal cortex. Genome-wide association analysis was used to investigate gene expression and, separately, DNA methylation for signals associated with the R2 measure. RESULTS: Of the 552 individuals with ex vivo imaging data, 394 were women and 158 were men, and the mean (SD) age at death was 90.4 (6.0) years. Four co-expressed genes (PADI2 [Ensembl ENSG00000117115], ZNF385A [Ensembl ENSG00000161642], PSD2 [Ensembl ENSG00000146005], and A2ML1 [Ensembl ENSG00000166535]) were identified, of which higher expressions were associated with slower R2. The association of R2 with cognitive decline was attenuated when the gene expression signals were added to the model, such that the mean (SE) coefficient of association was reduced from 0.028 (0.008) (P < .001) to 0.019 (0.009) (P = .03). The DNA methylation scan did not detect a genome-wide significant signal, but it revealed an anticorrelation between R2 and DNA methylation in many of the cytosine-guanine dinucleotides. CONCLUSIONS AND RELEVANCE: Brain gene expression and DNA methylation dysregulations are implicated in the alteration of brain tissue properties associated with late-life cognitive decline above and beyond the influence of common neuropathologic conditions.
引用
- Yu L, Dawe RJ, Boyle PA, et al. Association Between Brain Gene Expression, DNA Methylation, and Alteration of Ex Vivo Magnetic Resonance Imaging Transverse Relaxation in Late-Life Cognitive Decline. JAMA Neurol. 2017. PMID: 29084334. doi:10.1001/jamaneurol.2017.2807
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。